Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries
HIV, Hepatitis Continue To See Sales Declines
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.
You may also be interested in...
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
The CDC and FDA recommended a pause on dosing of J&J's one-shot vaccine. Pfizer/BioNTech's vaccine showed signs of lower efficacy against the B.1.351 variant, but a prominent expert called the data "misleading." Gilead halted its Phase III study of Veklury in non-hospitalized, high-risk patients. And Rigel's Tavalisse may have a shot in the sickest COVID-19 patients despite the small size of a Phase II study.
The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.